KRAS-Mutant Cancers: From Basic Biology to Clinical Translation
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 July 2025 | Viewed by 622
Special Issue Editors
Interests: chemotherapy; chemoresistance; cancer biology; colon cancer; cell signaling; proteomics; lipidomics; sphingolipids; biomarkers; personalised medicine
Special Issues, Collections and Topics in MDPI journals
Interests: colorectal cancer; KRAS; tumor microenvironment; therapy resistance
Special Issues, Collections and Topics in MDPI journals
Interests: molecular genetics; cancer; epigenetics; microbiota; gene therapy; genome editing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The RAS family of proteins is ubiquitously expressed in mammals and consists of KRAS, NRAS and HRAS isoforms. Among these, KRAS has the highest mutation rate and leads to a poor prognosis of cancer patients. KRAS is most frequently mutated in colorectal carcinoma, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. In addition, KRAS mutations are found in endometrial cancer, biliary tract malignancies, cervical cancer, liver cancer, bladder cancer, breast cancer and myeloid leukaemia. KRAS mutations result in the constitutive activation of KRAS protein that induces pro-proliferative and pro-survival signalling mediated by RAF/MEK/ERK and PI3K/AKT/mTOR, respectively, alter cell metabolism and impact the tumour microenvironment, leading to tumour initiation, progression and metastasis. Given its important role in tumour biology, KRAS is considered a promising drug target in oncology. However, the existence of different KRAS mutations that induce distinct signalling events in cancer renders KRAS signalling highly complex and poses a challenge in cancer treatment, especially considering distinct clinical features of the tumours bearing different KRAS mutations that exert different treatment responses and clinical outcomes. In addition, KRAS mutations co-exist with mutations in other genes such as PIK3CA, APC, EGFR and BRAF, which has important therapeutic and diagnostic implications in cancer. Despite significant progress in recent years in the development of KRAS-mutation-specific inhibitors leading to clinical approval of two KRASG12C inhibitors, Adagrasib and Sotorasib, the emergence of acquired resistance reduces their clinical benefits. For this reason, new combinatorial strategies should be explored to increase the clinical efficacy of KRAS inhibitors and improve the treatment outcomes in KRAS-mutant cancers. This Special Issue welcomes scientific contributions from basic, clinical and translational research that will broaden the current knowledge of the mutant KRAS-driven biology and genetics pertinent to tumour initiation, progression, metastasis and treatment to better understand the molecular and cellular consequences of KRAS mutations in cancer cells, and propose novel strategies to overcome therapeutic resistance in KRAS-mutant cancers.
Dr. Mirela Sedic
Dr. Sérgia Velho
Dr. Luka Bočkor
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- KRAS mutations
- KRAS signalling
- cancer
- KRAS inhibitors
- drug resistance
- tumour microenvironment
- cellular metabolism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
